Mylan CEO Tries to Shift Focus
/https://static.texastribune.org/media/images/syringes0001.png)
Amid numerous calls for state and federal investigations over pricing of its EpiPen, the drug company Mylan struck back, saying that 55 percent of the price goes to “middleman’’ insurers. (Becker’s Hospital Review)
Amid numerous calls for state and federal investigations over pricing of its EpiPen, the drug company Mylan struck back, saying that 55 percent of the price goes to “middleman’’ insurers. (Becker’s Hospital Review)